TNFRSF9 and melanoma: CD137 expression has recently been used to identify neoantigen-specific T cells[23] and promising data of a CD137 agonist in combination with PD-1 blockade therapy was recently presented in patients with melanoma (response rate 50% [23/46] with similar rates in patients with PD-L1 positive and negative tumors).